Download PDF
Thromb Haemost 2017; 117(04): 671-681
DOI: 10.1160/TH16-09-0691
Coagulation and Fibrinolysis
Schattauer GmbH

Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen

Ivan Ivanov
1   Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
Ruhama Shakhawat
1   Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
Mao-fu Sun
1   Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
S. Kent Dickeson
1   Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
Cristina Puy
2   Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA
,
Owen J.T McCarty
2   Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA
,
Andras Gruber
2   Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA
,
Anton Matafonov
1   Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
3   Department of Bioengineering and Organic Chemistry, Tomsk Polytechnic University, Tomsk, Russia
,
David Gailani
1   Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
› Author Affiliations Financial support: This study received financial support from awards HL81326 and HL58837 from the National Heart, Lung and Blood Institute.
Further Information

Publication History

Received: 09 September 2016

Accepted after major revision: 26 January 2016

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

The plasma zymogens factor XI (fXI) and prekallikrein (PK) are activated by factor XIIa (fXIIa) during contact activation. Polyanions such as DNA and RNA may contribute to thrombosis and inflammation partly by enhancing PK and fXI activation. We examined PK and fXI activation in the presence of nucleic acids, and determine the effects of the cofactor high molecular weight kininogen (HK) on the reactions. In the absence of HK, DNA and RNA induced fXI autoactivation. Proteases known to activate fXI (fXIIa and thrombin) did not enhance this process appreciably. Nucleic acids had little effect on PK activation by fXIIa in the absence of HK. HK had significant but opposite effects on PK and fXI activation. HK enhanced fXIIa activation of PK in the presence of nucleic acids, but blocked fXI autoactivation. Thrombin and fXIIa could overcome the HK inhibitory effect on autoactivation, indicating these proteases are necessary for nucleic acid-induced fXI activation in an HK-rich environment such as plasma. In contrast to PK, which requires HK for optimal activation, fXI activation in the presence of nucleic acids depends on anion binding sites on the fXI molecule. The corresponding sites on PK are not necessary for PK activation. Our results indicate that HK functions as a cofactor for PK activation in the presence of nucleic acids in a manner consistent with classic models of contact activation. However, HK has, on balance, an inhibitory effect on nucleic acid-supported fXI activation and may function as a negative regulator of fXI activation.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Contact phase - proteases - coagulation factors

 

  • References

  • 1 Müller F, Mutch NJ, Schenk WA. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156
    CrossrefPubMedSearch in Google Scholar
  • 2 Morrissey JH, Choi SH, Smith SA.. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972-5979
    CrossrefPubMedSearch in Google Scholar
  • 3 Kannemeier C, Shibamiya A, Nakazawa F. et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-6393
    CrossrefPubMedSearch in Google Scholar
  • 4 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885
    CrossrefPubMedSearch in Google Scholar
  • 5 Fischer S, Preissner KT.. Extracellular nucleic acids as novel alarm signals in the vascular system. Mediators of defense and disease. Hamostaseologie 2013; 33: 37-42
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Pinegin B, Vorobjeva N, Pinegin V.. Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev 2015; 14: 633-640
    CrossrefPubMedSearch in Google Scholar
  • 7 Brill A, Fuchs TA, Savchenko AS. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136-144
    CrossrefPubMedSearch in Google Scholar
  • 8 Long AT, Kenne E, Jung R. et al. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost 2016; 14: 427-437
    CrossrefPubMedSearch in Google Scholar
  • 9 Schmaier AH.. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J Thromb Haemost 2016; 14: 28-39
    CrossrefPubMedSearch in Google Scholar
  • 10 Danese E, Montagnana M, Lippi G.. Factor XII in hemostasis and thrombosis: active player or (innocent) bystander?. Semin Thromb Hemost 2016; 42: 682-688
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Wiggins RC, Bouma BN, Cochrane CG, Griffin JH.. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci USA 1977; 74: 4636-4640
    CrossrefPubMedSearch in Google Scholar
  • 12 Thompson RE, Mandle Jr R, Kaplan AP.. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci USA 1979; 76: 4862-4866
    CrossrefPubMedSearch in Google Scholar
  • 13 Revenko AS, Gao D, Crosby JR. et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311
    CrossrefPubMedSearch in Google Scholar
  • 14 Renné T, Pozgajová M, Grüner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281
    CrossrefPubMedSearch in Google Scholar
  • 15 Cheng Q, Tucker EI, Pine MS. et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981-3989
    CrossrefPubMedSearch in Google Scholar
  • 16 Matafonov A, Leung PY, Gailani AE. et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123: 1739-1746
    CrossrefPubMedSearch in Google Scholar
  • 17 Bird JE, Smith PL, Wang X. et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107: 1141-1150
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Stavrou EX, Fang C, Merkulova A. et al. Reduced thrombosis in Klkb1-/-mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood 2015; 125: 710-719
    CrossrefPubMedSearch in Google Scholar
  • 19 Merkulov S, Zhang WM, Komar AA. et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281
    PubMedSearch in Google Scholar
  • 20 Wendel HP, Jones DW, Gallimore MJ.. FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery. Immunopharmacology 1999; 45: 141-144
    CrossrefPubMedSearch in Google Scholar
  • 21 Plötz FB, van Oeveren W, Bartlett RH, Wildevuur CR.. Blood activation during neonatal extracorporeal life support. J Thorac Cardiovasc Surg 1993; 105: 823-832
    CrossrefPubMedSearch in Google Scholar
  • 22 Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI.. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 2015; 13 Suppl (01) S72-81
    CrossrefPubMedSearch in Google Scholar
  • 23 Gailani D, Bane CE, Gruber A.. Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost 2015; 13: 1383-1395
    CrossrefPubMedSearch in Google Scholar
  • 24 Fujikawa K, Chung DW, Hendrickson LE, Davie EW.. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25: 2417-2424
    CrossrefPubMedSearch in Google Scholar
  • 25 Ponczek MB, Gailani D, Doolittle RF.. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost 2008; 6: 1876-1883
    CrossrefPubMedSearch in Google Scholar
  • 26 Naito K, Fujikawa K.. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-7358
    PubMedSearch in Google Scholar
  • 27 Gailani D, Broze Jr. GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912
    CrossrefPubMedSearch in Google Scholar
  • 28 von dem Borne PA, Mosnier LO, Tans G, Meijers JC, Bouma BN.. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost 1997; 78: 834-839
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D.. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114: 452-458
    CrossrefPubMedSearch in Google Scholar
  • 30 Matafonov A, Sarilla S, Sun MF. et al. Activation of factor XI by products of prothrombin activation. Blood 2011; 118: 437-445
    CrossrefPubMedSearch in Google Scholar
  • 31 Choi SH, Smith SA, Morrissey JH.. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970
    CrossrefPubMedSearch in Google Scholar
  • 32 Geng Y, Verhamme IM, Smith SB. et al. The dimeric structure of factor XI and zymogen activation. Blood 2013; 121: 3962-3969
    CrossrefPubMedSearch in Google Scholar
  • 33 Gould TJ, Vu TT, Swystun LL. et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 2014; 34: 1977-1984
    CrossrefPubMedSearch in Google Scholar
  • 34 Tucker EI, Marzec UM, White TC. et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009; 113: 936-944
    CrossrefPubMedSearch in Google Scholar
  • 35 Kokoye Y, Ivanov I, Cheng Q. et al. A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thromb Res 2016; 140: 118-124
    CrossrefPubMedSearch in Google Scholar
  • 36 Geng Y, Verhamme IM, Messer A. et al. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem 2012; 287: 38200-38209
    CrossrefPubMedSearch in Google Scholar
  • 37 Geng Y, Verhamme IM, Smith SA. et al. Factor XI anion-binding sites are required for productive interactions with polyphosphate. J Thromb Haemost 2013; 11: 2020-2028
    CrossrefPubMedSearch in Google Scholar
  • 38 Zhao M, Abdel-Razek T, Sun MF, Gailani D.. Characterization of a heparin binding site on the heavy chain of factor XI. J Biol Chem 1998; 273: 31153-31159
    CrossrefPubMedSearch in Google Scholar
  • 39 Yang L, Sun MF, Gailani D, Rezaie AR.. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry 2009; 48: 1517-1524
    CrossrefPubMedSearch in Google Scholar
  • 40 Gailani D, Broze Jr. GJ. Effects of glycosaminoglycans on factor XI activation by thrombin. Blood Coagul Fibrinolysis 1993; 4: 15-20
    CrossrefPubMedSearch in Google Scholar
  • 41 Thompson RE, Mandle Jr R, Kaplan AP.. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-1380
    CrossrefPubMedSearch in Google Scholar
  • 42 Scott CF, Silver LD, Purdon AD, Colman RW.. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function J Biol Chem 1985; 260: 10856-10863
    PubMedSearch in Google Scholar
  • 43 Vu TT, Leslie BA, Stafford AR. et al. Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. Thromb Haemost 2016; 115: 89-98
    Thieme ConnectPubMedSearch in Google Scholar
  • 44 Gansler J, Jaax M, Leiting S. et al. Structural requirements for the procoagulant activity of nucleic acids. PLoS One 2012; 7: e50399
    CrossrefPubMedSearch in Google Scholar
  • 45 Nakazawa F, Kannemeier C, Shibamiya A. et al. Extracellular RNA is a natural cofactor for the auto-activation of Factor VII-activating protease (FSAP). Biochem J 2005; 385: 831-838
    CrossrefPubMedSearch in Google Scholar
  • 46 Gailani D, Broze Jr. GJ. Factor XI activation by thrombin and factor XIa. Semin Thromb Hemost 1993; 19: 396-404
    Thieme ConnectPubMedSearch in Google Scholar
  • 47 Wheeler AP, Gailani D.. Why factor XI is a clinical concern. Expert Rev Hematol 2016; 9: 629-637
    CrossrefPubMedSearch in Google Scholar